SEQIRUS has announced the manufacture of an additional 500,000 doses of adult influenza vaccine, Afluria Quad (inactivated quadrivalent influenza vaccine, split virion) for the National Immunisation Program (NIP) ahead of schedule, with the first of the vaccines to be released this week.
Seqirus was asked to go back into production by the government due to an increase in demand for vaccine on the back of a severe influenza season last year.
In addition, Seqirus also made the decision to manufacture 200,000 extra doses for the private market.
Commercial Operations vice president Dr Lorna Meldrum said, "Our team has been working around the clock, seven days a week to produce an additional 700,000 doses for Australia".
Supply from the Parkville, Victoria site will continue to be released over the coming weeks, she added.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jul 18
